| 11.13.23 | Novartis aims to be CAR-T Legend with $100M deal; Verve's human base editing data disappoint investors

Laden...

1 jaar geleden

Html
Tekst


A message from bioduro-sundia

Today’s Big News

Nov 13, 2023

Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment

Verve shows base editing works in humans in first clinical data—and is punished by investors

AstraZeneca's long-term GLP-1 play is weight management, not obesity, CEO says

Selecta fuses with Cartesian in reverse merger, bolstering finances for autoimmune cell therapy goals

Imbria goes 2 for 2, hitting safety goal in angina trial days after racking up heart failure win

Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program

Aclaris' stock sinks further as biotech abandons MK2 inhibitor over latest phase 2 fail

Basilea continues pipeline fill-up by paying Pfizer $37M for Amplyx antifungal


A message from Science 37

Featured

Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment

By James Waldron

Novartis is going to give a solid-tumor-focused cell therapy the T-Charge treatment after paying $100 million upfront to Legend Biosciences for a selection of CAR-T candidates.

Verve shows base editing works in humans in first clinical data—and is punished by investors

By Nick Paul Taylor

Verve Therapeutics has published the first data on an in vivo base editing program in humans, giving the world an early look at the effects of a cholesterol-busting candidate that could become part of Eli Lilly’s stable of heart disease drugs. But investors pummeled the stock amid potential safety concerns.

AstraZeneca's long-term GLP-1 play is weight management, not obesity, CEO says

By Max Bayer

A day after AstraZeneca inked a new $185 million licensing deal to reenter the GLP-1 frenzy, CEO Pascal Soriot says the future marketplace will center less on treating obesity and more on sustained weight management.

2023 Executive Interviews at Fierce Biotech Summit and New Product Planning

Improve DNA sequence accuracy with a scalable prep that preserves precious material

Reduce sequence artifacts that dampen variant calling sensitivity. Prepare highly complex libraries in under 1.5 hours, and minimize damage and loss with precious low-input and FFPE material. Learn more.

Selecta fuses with Cartesian in reverse merger, bolstering finances for autoimmune cell therapy goals

By Max Bayer

Selecta is reverse merging with Cartesian to bolster its cash coffers and add a lifeline in a difficult public market. The focus of the new venture will be Cartesian's cell therapy aimed at autoimmune diseases.

Imbria goes 2 for 2, hitting safety goal in angina trial days after racking up heart failure win

By Nick Paul Taylor

Midphase data are arriving thick and fast at Imbria Pharmaceuticals. Days after sharing positive top-line data in one indication, the cardiometabolic biotech has reported a phase 2 trial of the same candidate in a different setting has met its primary endpoint.

Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program

By Gabrielle Masson

VectorY Therapeutics has secured €129 million ($138 million) in a series A financing that will help the Dutch biotech advance its preclinical lead program in ALS.

Aclaris' stock sinks further as biotech abandons MK2 inhibitor over latest phase 2 fail

By James Waldron

Aclaris Therapeutics has abandoned its immuno-inflammatory plans for zunsemetinib after the latest phase 2 fail saw the MK2 inhibitor unable to match placebo on any primary or secondary endpoints in a rheumatoid arthritis trial.

Basilea continues pipeline fill-up by paying Pfizer $37M for Amplyx antifungal

By James Waldron

Only two and a half years after Pfizer acquired infectious disease biotech Amplyx for an undisclosed sum, the Big Pharma has sold the lead antifungal asset from that deal to Basilea Pharmaceutica.

Capturing COVID: Biopharma through the lens during the pandemic

By Angus Liu

A few months ago, Fierce Pharma asked employees working in the biopharma industry to use photographs to tell their stories during the pandemic. Now, we’re showcasing those precious memories here.

FDA clears its first OTC home antigen test for COVID-19. No, really

By Conor Hale

No, you didn’t set your clocks too far back. This week, the FDA granted its first full, bona fide clearance to an over-the-counter home antigen test for COVID-19, after hundreds of emergency authorizations.

Madrigal, eyeing a NASH drug launch in 2024, nabs Dupixent commercial mastermind Carole Huntsman as CCO

By Ben Adams

Madrigal Pharmaceuticals has hired Carole Huntsman as its new chief commercial officer to help the biotech navigate a new and potentially tricky launch in NASH.

NYU Langone completes first whole-eye transplant with support from J&J's DePuy Synthes

By Andrea Park

In a world-first procedure earlier this year, a vast team of surgeons and OR staff at NYU Langone Health successfully performed a whole-eye and partial-face transplant on a man who had survived a high-voltage electrical accident, the hospital announced this week.

GSK, fresh from Ojjaara approval, allies with ex-"Queer Eye" star to run myelofibrosis education campaign

By Nick Paul Taylor

GSK is building its presence in the myelofibrosis community. Working with interior designer and former "Queer Eye" star Thom Filicia, the Big Pharma is launching the Mapping Myelofibrosis health education initiative to support patients with the blood cancer treated by its recently approved drug Ojjaara.

Report: High wait times, poor reimbursement drive autism diagnosis delays

By Anastassia Gliadkovskaya

Nearly two-thirds of specialty centers that conduct autism evaluations have wait times longer than four months, according to a new report.

Fierce podcasts

Don’t miss an episode

Psychedelics and the next frontier of mental healthcare

In this episode of “The Top Line,” we explore the next potential wave of mental health therapy: psychedelics.

'Podnosis': Leading with empathy amid crisis

Exploring the promise of earlier Alzheimer's treatment


A message from Promab Biotechnologies

Resources

Webinar

Reimagine the infrastructure that makes science possible

Watch now to explore the convergence of science, capital, operational excellence and workplace strategy.

Overcome Challenges and Secure Successful Technology Transfers of Complex Biological Products in Sterile Manufacturing

A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer.

Enhance the cost-effectiveness of your GMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows.

Sponsored by: Thermo Fisher Scientific Production Chemicals and Services

Whitepaper

Plasmid DNA Design Considerations for Cell and Gene Therapy

Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications.

Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins

Whitepaper

Artificial Intelligence in Healthcare & Medical Affairs

This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders.

Presented by Blue Matter, strategic consultants in the life sciences

eBook